FiercePharma |
Celgene off-label marketing lawsuit documents unsealed
FiercePharma Celgene ($CELG) has successfully fought off several lawsuits suggesting the success of its blockbuster multiple myeloma meds Revlimid and Thalomid relied on aggressive off-label marketing. A California whistleblower case, however, has moved forward ... |
August 25, 2016 at 01:12PM | marketing - Google News
Celgene off-label marketing lawsuit documents unsealed - FiercePharma
marketing - Google News
Nenhum comentário:
Postar um comentário